91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of Chicago, University of Chicago Medical Center, The University of Texas MD Anderson Cancer Center, Angeles Clinic and Research Institute, Clinica Universidad de Navarra, University of California Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Davis, The Christie Hospital, The Christie NHS Foundation Trust, OU Health Stephenson Cancer Center, University of Oklahoma, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, University of Colorado Health, University of Colorado Cancer Center, University of Colorado Anschutz, Sarah Cannon Research Institute, University of Glasgow, Sarah Cannon, Immunocore (United Kingdom), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4200370560